David F Kronn MD
Medical Genetics
Associate Professor, Pediatrics, New York Medical College
Join to View Full Profile
Regional Medical Genetics503 Grasslands Road Suite 200Valhalla, NY 10595
Phone+1 914-304-5280
Fax+1 914-345-1753
Dr. Kronn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Pediatrics, 1990 - 1996
University of Dublin Trinity CollegeClass of 1989
Certifications & Licensure
NY State Medical License 1993 - 2027
CT State Medical License 1998 - 2025
American Board of Medical Genetics and Genomics Clinical Biochemical Genetics- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2012-2014
- America's Top Doctors Castle Connolly, 2012-2014
- Top Doctors: New York Metro Area Castle Connolly, 2010-2014
- Join now to see all
Clinical Trials
- An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treate...David Kronn, James Davison, Alexander Broomfield, Anaïs Brassier, François Labarthe
The Journal of Pediatrics. 2025-10-01 - 6 citationsHigher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry.Priya S Kishnani, David Kronn, Shugo Suwazono, Alexander Broomfield, Juan Llerena
Orphanet Journal of Rare Diseases. 2023-12-06 - 33 citationsSafety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: The 6-month primary...Priya S Kishnani, David Kronn, Anaïs Brassier, Alexander Broomfield, James Davison
Genetics in Medicine. 2023-02-01
Press Mentions
Sanofi’s Next-Generation ERT Halts Progression of Pompe Disease in Patients, Interim Trial Data ShowFebruary 13th, 2020
High Prices for Orphan Drugs Strain Families and InsurersJanuary 17th, 2017- Sky-High Prices for Orphan Drugs Slam American Families and InsurersJanuary 17th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
